<--- Back to Details
First PageDocument Content
Epigenetics / Acute leukemia / Myeloid leukemia / Acute myeloid leukemia / Transcription factors / DNA methyltransferase / Myelodysplastic syndrome / RUNX1 / MECOM / Biology / Oncology / Genetics
Epigenetics
Acute leukemia
Myeloid leukemia
Acute myeloid leukemia
Transcription factors
DNA methyltransferase
Myelodysplastic syndrome
RUNX1
MECOM
Biology
Oncology
Genetics

The Epigenetic Landscape of Acute Myeloid Leukemia

Add to Reading List

Source URL: www.ncbi.nlm.nih.gov

Download Document from Source Website

File Size: 1,22 MB

Share Document on Facebook

Similar Documents

The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model  Mouse-1 Mouse-2

The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2

DocID: 1uSbg - View Document

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

DocID: 1uJQ2 - View Document

Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling Ingrid G Winkler, PhD1*, Johanna M Erbani, PhD student2*,

Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling Ingrid G Winkler, PhD1*, Johanna M Erbani, PhD student2*,

DocID: 1u5Xi - View Document

Regulatory Perspective: Acute Leukemia Clinical Endpoints Nancy S. Scher, MD, FACP DODP, CDER, FDA 1

Regulatory Perspective: Acute Leukemia Clinical Endpoints Nancy S. Scher, MD, FACP DODP, CDER, FDA 1

DocID: 1tdCV - View Document

· ACUTE LYMPHOBL ASTIC LEUKEMIA ·  Incorporating Antibodies into Treatment Strategies for Acute Lymphoblastic Leukemia Nicholas J. Short, MD, and Elias Jabbour, MD

· ACUTE LYMPHOBL ASTIC LEUKEMIA · Incorporating Antibodies into Treatment Strategies for Acute Lymphoblastic Leukemia Nicholas J. Short, MD, and Elias Jabbour, MD

DocID: 1shAS - View Document